Literature DB >> 6989972

Prevalence of type-specific group B streptococcal antibody in pregnant women.

L C Vogel, K M Boyer, C A Gadzala, S P Gotoff.   

Abstract

Immunoglobulin G antibody against the four major serotypes of group B streptococcus was measured by indirect immunofluorescence in the sera of 200 consecutive pregnant women seen in the obstetric screening clinic of an urban teaching hospital. Antibody was detectable in 26% of undiluted sera against serotype Ia, 52% against serotype Ib, 82% against serotype II, and 45% against serotype III. Only 9% had antibody against all four GBS types. When serotype-specific antibody prevalences in 108 women with GBS vaginal colonization were compared with prevalences in noncolonized women, only women colonized with GBS type Ia were more likely to have antibody against Ia than noncolonized women. Antibody prevalences in sera from 54 mothers whose infants developed invasive GBS disease were significantly lower than those in colonized or noncolonized women. Since low titers of IF antibody to GBS III were present in some sera from mothers of infected infants, the data were analyzed based on IF antibody titers associated with passive protection in a chick embryo model of GBS septicemia. None of the sera from mothers of infected infants had antibody levels associated with chick embryo protection. Less than 10% of women had titers associated with chick embryo protection. These data suggest that the majority of pregnant women lack immunity to GBS, regardless of colonization status.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6989972     DOI: 10.1016/s0022-3476(80)80639-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  The clinical use of intravenous immunoglobulin in pediatrics.

Authors:  V Wahn
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

2.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Immunospecificity and quantitation of an enzyme-linked immunosorbent assay for group B streptococcal antibody.

Authors:  B F Anthony; N F Concepcion; S A McGeary; J I Ward; D C Heiner; P Shapshak; R A Insel
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

4.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

5.  Seroprevalence of antibodies to group B streptococcal polysaccharides in Gambian mothers and their newborns.

Authors:  R O Suara; R A Adegbola; E K Mulholland; B M Greenwood; C J Baker
Journal:  J Natl Med Assoc       Date:  1998-02       Impact factor: 1.798

6.  Opsonization of group B Streptococcus type III: studies using clinical strains and maternal sera.

Authors:  M J Hastings; J Neil; C S Easmon
Journal:  Br J Exp Pathol       Date:  1985-06

7.  Protective levels of human immunoglobulin G antibody to group B streptococcus type Ib.

Authors:  K M Boyer; L S Kendall; C K Papierniak; M E Klegerman; S P Gotoff
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

8.  Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.

Authors:  M E Klegerman; K M Boyer; C K Papierniak; L Levine; S P Gotoff
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

9.  Hypersusceptibility of penicillin-treated group B streptococci to bactericidal activity of human polymorphonuclear leukocytes.

Authors:  D Horne; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  Intravenous administration of human IgG to newborn infants: changes in serum antibody levels to group B streptococci.

Authors:  K K Christensen; P Christensen; H U Bucher; G Duc; C H Kind; D Mieth; B Müller; R A Seger
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.